SARS-CoV-2 - Azithromycin - Therapeutic Candidates

SARS-CoV-2 - Azithromycin - Therapeutic Candidates


Azithromycin is a macrolide antibiotic. This broad-spectrum antibiotic of the azalide group is a derivative of erythromycin. Azithromycin is indicated for the treatment of certain types of mild to moderate infections caused by bacteria. Most commonly, it is used to treat ear infections such as otitis media, throat and lung infections such as pharyngitis and pneumonia, and certain skin infections. Azithromycin is also prescribed to patients with cystic fibrosis because they are particularly susceptible to respiratory infections.
A recent study, in the context of the Covid-19 epidemic currently affecting many countries around the world, sought to investigate the effect of azithromycin in combination with hydroxychloroquine. The interest in azithromycin came from the fact that the rate of Covid-19 infection was low in a large cohort of patients with cystic fibrosis, many of whom are on azithromycin therapy.

Search result : 277 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 38
  • Biochemicals 231
  • Inhibitor/Antagonist/Agonist 42
  • Buffers and reagents 2
  • cell culture products 2
  • Assay 3
  • Cell culture 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
458788-500ug
 500ug 
TRC-A927004-1MG
 1mg 
442034-500ug
 500ug 
B1398-25mg
 25mg 
B1398-1ml
 10mM(in1mLDMSO) 
257274-25mg
 25mg 
257274-50mg
 50mg 
257274-100mg
 100mg 
257274-250mg
 250mg 
008532-25mg
 25mg 
008297-25mg
 25mg 
A-2667-25MG
 25MG 
257274-10mg
 10mg 
AOB17614-1
 1mg 
AOB17614-50
 50mg 
AOB17614-100
 100mg 
AOB17614-5
 5mg 
AOB17614-10
 10mg 
AOB17614-25
 25mg 
TRC-A927018-25MG
 25mg